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A B S T R A C T
Over the last three decades there is an increasing number of investigators and meta-
analyses focusing on the dangers of lo�ering blood pressure belo� certain levels. Sev-
eral studies such as Invest, Ontarget, Value and TNT sho�ed a significant decrease 
in cardiovascular morbidity and mortality by lo�ering blood pressure levels. Ho�ever, 
blood pressure decrease belo� a certain level had exactly the opposite effect. The 
increase of cardiovascular morbidity and mortality �as attributed to the excessive re-
ductions in blood pressure �hich may explain �hy in major clinical trials blood pres-
sure belo� certain levels increases cardiovascular adverse events mainly in patients 
�ith coronary heart disease. In these patients a fall in diastolic blood pressure might 
lo�er perfusion pressure distal to a stenosis belo� a critical level at �hich autoregu-
lation is effective. This phenomenon led the European Society of Hypertension to 
propose a “J-shaped curve” relationship bet�een blood pressure and cardiac morbid-
ity and mortality, �hereby lo�ering blood pressure belo� a critical point is no longer 
beneficial and possibly even deleterious. The challenge is to better define the limits of 
intervention and to define groups of people �ho are particularly vulnerable to over-
aggressive lo�ering of blood pressure.
Hypertension is an established risk factor for major cardiovascular events; its entity 
�as recognized from antiquity, even �ith different definition (“hard pulse disease”), 
�here ancient historical records as far back as 2600 BC report different treatment 
strategies (usually by acupuncture and venesection) to manage this disease.1 Over the 
years treatment strategies �ere changed; in the late 1930s, elevated blood pressure 
�as considered by many expert physicians to be necessary for the adequate perfusion 
of vital organs; JH Hay affirms that “the greatest danger to a man �ith high blood 
pressure lies in its discovery, because then some fool is certain to try and reduce it”.2 
Like�ise, P Dudley White affirms that “Hypertension may be an important compensa-
tory mechanism �hich should not be tampered �ith, even if it �ere certain that �e could 
control it”.3 In the late 1950s, the benefit of blood pressure reduction reappears �ith 
the introduction of diuretics4 and the research for effective therapy and management of 
hypertension continued until the 1990s �ere the dogma “the lo�er the better” prevails 
after the HOT study results.5 The zeal of the physicians �as so pronounced that they 
�ere tempted to decrease blood pressure especially diastolic blood pressure as lo�est 
as possible �ithout adverse effects, encouraged by contemporary guidelines in 1980s.6 
Ho�ever, in the last three decades there have been an increasing number of inves-
tigators and meta-analyses focusing on the dangers of lo�ering blood pressure belo� 
HYPERLIPIDEMIA & HYPERTENSION UPDATE
Cardiology Department, Asklepeion 
General Hospital, Athens, Greece
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 136–138
Correspondence to:
Dr. Manolis S. Kallistratos, 
Cardiology Department, Asklepeion 
General Hospital, 
1 Vasileos Pavlou str., Voula, 16673, 
Athens, Greece;  
Tel: +30-213-2163365/  
Fax: +30- 210-8923209; 
e-mail: kallistrat1972@gmail.com
KEY WORDS: hypertension; J-curve 
phenomenon; cardiovascular risk; 
coronary heart disease
Conflict of Interest: none declared
HYPERTENSION & J-CURVE
137
certain levels. Several studies such as Invest, Ontarget, Value 
and TNT7 sho�ed a significant decrease in cardiovascular 
morbidity and mortality by lo�ering blood pressure levels. 
Ho�ever, blood pressure decrease belo� a certain level had 
exactly the opposite effect.7 The increase of cardiovascular 
morbidity and mortality �as attributed to the excessive re-
ductions in blood pressure �hich may explain �hy in major 
clinical trials blood pressure belo� certain levels increases 
cardiovascular adverse events mainly in patients �ith coro-
nary heart disease. Many authors attribute this phenomenon 
mainly among other reasons to the fact that most of coronary 
blood flo� to the left ventricle occurs in diastole. In patients 
�ith chronic ischemic heart disease a fall in diastolic blood 
pressure might lo�er perfusion pressure distal to a stenosis 
belo� a critical level at �hich autoregulation is effective. This 
phenomenon leads the European Society of Hypertension to 
propose a “J-shaped curve” relationship bet�een blood pres-
sure and cardiac morbidity and mortality, �hereby lo�ering 
blood pressure belo� a critical point is no longer beneficial 
and possibly even deleterious.7 The J curve describes the 
shape of the relationship bet�een blood pressure and the risk 
of cardiovascular morbidity and/or mortality and the J shape 
reflects increased risk at high levels of blood pressure, �ith risk 
falling in parallel to blood pressure reduction until a nadir is 
reached, belo� �hich further blood pressure reduction begins 
to increase the risk.
Ho�ever, the explanation of this blood pressure paradox 
seems to be more complicated. A plethora of reports have 
described the shape of the relationship bet�een blood pres-
sure and risk. Some reports have sho�n this relationship to be 
continuous and positive, �hile others have demonstrated an 
increased risk in participants �ith lo� blood pressure. Ho�-
ever, these studies lacked control patients, thus, comparison 
�ith similar but untreated patients �as impossible. These 
reports could not investigate �hether drugs that reduce blood 
pressure have harmed hypertensive patients or it �as lo� blood 
pressure or co-morbidities from the beginning that increased 
cardiovascular events. The INDANA database offered the 
opportunity to assess the shape of the relationship bet�een 
risk for events and level of blood pressure in both treated and 
initially untreated hypertensive patients.8 The authors affirmed 
that the increased risk for events observed in patients �ith 
lo� blood pressure �as not related to antihypertensive treat-
ment and �as not specific to blood pressure–related events. 
They attributed the J-shaped curve as due to the poor health 
conditions that lead to lo� blood pressure and an increased 
risk for death.8 
Therefore, there are different opinions regarding the same 
issue and critical questions remain to be ans�ered.
Ho� lo� can blood pressure be lo�ered and remain both 
safe and beneficial?
What is the lo�est safe level of blood pressure beyond 
�hich potential harm offsets the benefits of treatment?
Whether the J-curve relationship is equally significant for 
systolic as it is for diastolic blood pressure and �hether its 
impact is more relevant for stroke, renal events, myocardial 
infarction and heart failure 
According to the guidelines of the European Society of 
Hypertension (ESH), in the general hypertensive population 
the blood pressure target is <140/90 mmHg and in high risk 
patients �ith coronary artery disease, stroke, diabetes or renal 
dysfunction, the target is <130/80 mmHg. The concept in the 
latter group is that of a flexible threshold/target for treatment 
in relation to total cardiovascular risk due to J-curve phe-
nomenon.7 Ho�ever, there is no evidence for this affirmation 
since there are practically no data regarding the beneficial 
effect of lo�ering blood pressure belo� this threshold in this 
high risk group. 
In the ACCORD study, the authors concluded that in pa-
tients �ith type 2 diabetes at high risk for cardiovascular events, 
targeting a systolic blood pressure of less than 120 mmHg, as 
compared �ith less than 140 mmHg, did not reduce the rate 
of a composite outcome of fatal and nonfatal major cardio-
vascular events.9 Moreover, in the HOT study, reanalyzing the 
data, there �as no evidence of a J-shaped curve for the relation 
of major cardiovascular events, myocardial infarction, stroke, 
and cardiovascular mortality �ith achieved blood pressures.
Based on the previously published trials, it seems that there 
is no J curve for stroke and renal events, ho�ever in the field 
of coronary heart disease �e need �ell designed prospective 
randomized studies to ans�er the question for the existence of 
a J curve or not. Clearly, there is a point at �hich both diastolic 
and systolic blood pressure become too lo� to sustain life.
In conclusion, advanced cardiovascular disease is a mixture 
of different clinical conditions �hich require individualization 
of decisions. Despite the need to reduce cardiovascular risk 
by blood pressure reduction, blood pressure control is more 
difficult to achieve due to the presence of underlying vascular 
and renal organ damage. The challenge is to better define the 
limits of intervention and to define groups of people �ho are 
particularly vulnerable to over-aggressive lo�ering of blood 
pressure; to this end, �e are in dire need for ne� prospective 
randomized trials addressing this question.
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